clopidogrel and adenosine

clopidogrel has been researched along with adenosine in 570 studies

Research

Studies (570)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.18)	18.2507
2000's	32 (5.61)	29.6817
2010's	521 (91.40)	24.3611
2020's	16 (2.81)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Colman, RF; Colman, RW; Freedman, MD; Grana, G; Hu, CJ; Mills, DC; Minniti, C; Puri, R	1
Guile, SD; Ince, F; Ingall, AH; Kindon, ND; Meghani, P; Mortimore, MP	1
Kelly, AB; Levy, JH; Szlam, F; Tanaka, KA; Vega, JD	1
Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G	1
Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M	1
Gurbel, PA; Tantry, US	2
Cattaneo, M	6
Roe, MT; Steinhubl, S	1
de Lemos, JA; Wiviott, SD	1
Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF	1
Angiolillo, DJ	1
Barker, CM; Price, MJ	1
Eikelboom, JW; Hirsh, J; Raju, NC	1
Akram, F; Akram, S; Postuła, M	1
Husted, S	2
Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L	1
Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Mitchell, P; Storey, RF	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Makarov, LM; Serebruany, VL	1
Husted, S; van Giezen, JJ	1
Armstrong, M; Cannon, CP; Emanuelsson, H; Heptinstall, S; Husted, S; Lawrance, R; Melissa Thornton, S; Storey, RF; Wickens, M	1
Kumar, A; Roberts, DH	1
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H	1
Schömig, A	1
Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L	1
Eshaghian, S; Kaul, S; Shah, PK	1
Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V	1
Bhatt, DL	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
del Río, A; Heras, M	1
Tomoda, H	1
Atar, D; Serebruany, VL	1
Serebruany, VL	8
Parra, D; Rosenstein, RS	1
Lotfi, A; Rothberg, M; Wartak, SA	1
Jilma, B; Krumphuber, J; Siller-Matula, JM	1
Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D	1
Stone, GW	1
Anderson, SD; Epstein, BJ; Shah, NK; Yim, J	1
Preobrazhenskiĭ, DV	1
Cattaneo, M; Podda, GM	1
Antonino, MJ; Bliden, KP; Butler, K; Eikelboom, JW; Gurbel, PA; Henderson, D; Husted, S; Kereiakes, DJ; Nielsen, T; Patel, DV; Rasmussen, L; Sabe-Affaki, G; Storey, RF; Tantry, US; Teng, R; Wei, C	1
Lip, GY; Shantsila, E; Tapp, L	1
Antonijević, N; Antović, J; Baskot, B; Djenić, N; Dopudja, M; Gligić, B; Grdenić, A; Jovelić, A; Miković, D; Obradović, S; Salinger, S; Subota, V; Vukotić, S	1
Guo, KW; Tan, JW	1
Aylward, PE; Behan, MW; Chew, DP	1
Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF	1
Chew, DP; Prakash, R; Wong, YW	1
Adams, HP	1
Dixon, SR; Grines, CL; O'Neill, WW	1
Erdem, G; Flather, MD; Geisler, T	1
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS	1
Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C	1
Butler, K; Teng, R	1
Gratsianskiĭ, NA	1
Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X	1
Aïssaoui, N; Danchin, N	1
Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L	1
Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L	1
Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D	1
Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L	1
Ardissino, D; Caracciolo, M; D'Urbano, M; De Servi, S	1
Morais, J	1
Radke, PW; Schunkert, H	1
Abergel, E; Nikolsky, E	1
Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD	1
Pollack, CV	1
Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C	1
Beitelshees, AL	1
Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C	1
Fusco, JA; Huang, NS; Master, HH; Park, ZH	1
Jilma, B; Siller-Matula, JM	1
Frey, N; Ivandic, B	1
Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J	1
Schneider, DJ	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M	1
Gaglia, MA; Waksman, R	1
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD	1
Hamm, CW; Rassaf, T	1
Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M	1
White, HD	1
Ohman, EM; Roe, MT	1
Becker, RC; Harrington, RA; James, SK; Wallentin, L	1
Scharf, RE	1
Storey, RF	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L	1
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M	1
Cattaneo, GJ; Cattaneo, M; Podda, GM	1
Easton, JD	1
Moliterno, DJ; Rajan, L	1
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC	1
Timmis, A	1
Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L	1
Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Storey, RF; Tantry, U; Wei, C	1
Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM	1
Bliden, KP; Gesheff, M; Gurbel, PA; Jeong, YH; Storey, RF; Tantry, US; Wei, C	1
Alber, HF; Frick, M; Huber, K; Pachinger, O	1
Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G	1
Becker, RC; Cairns, R; Cannon, CP; Cools, F; Cooper, A; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Khurmi, NS; Steg, PG; Storey, RF; Wallentin, L	1
Hinneburg, I	1
Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L	1
Chauhan, A; More, RS; Morgan, KP	1
D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S	1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J	2
De Mey, JG; Feijge, MA; Heemskerk, JW; Kuijpers, MJ; Megens, RT; Nikookhesal, E; oude Egbrink, MG; van Giezen, JJ	1
Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM	1
Basra, SS; Lakkis, NM; Tsai, P	1
Brilakis, ES; de Lemos, JA	1
Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L	1
Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM	1
Jeger, R; Kaiser, C; Pfisterer, M	1
Collet, JP; De Luca, L; Wouter Jukema, J	1
Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P	1
Braunwald, E	1
Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL	1
Janknegt, R; Ruiters, L; Ten Cate, H	1
Calvi, V; Capodanno, D; Tamburino, C	1
Davies, JE; Francis, DP; Nijjer, SS	1
Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L	1
Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM	1
Kern, MJ	1
Contractor, H; Ruparelia, N	1
Grześk, G; Koziński, M; Kubica, J	1
Grajek, S	1
Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C	1
Lavi, R; Lavi, S	1
Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y	1
Held, C	1
Ferro, A; Floyd, CN; Passacquale, G	1
Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF	1
Verheugt, FW	1
Angiolillo, DJ; Azmoon, S	1
Mustonen, P; Puurunen, M	1
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA	1
Alexopoulos, D; Goudas, P; Goumenos, D; Koutroulia, E; Plakomyti, TE; Xanthopoulou, I	1
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T	1
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F	1
Heptinstall, S; Joshi, R; Wijeyeratne, YD	1
Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L	1
Ahmad, S; Storey, RF	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Barn, K; Steinhubl, SR	1
Grove, EL; Hvas, AM; Kristensen, SD	1
Budaj, A; Gurbel, PA; Tantry, US	1
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I	1
Antonino, MJ; Bliden, KP; Gurbel, PA; Jeong, YH; Park, KS; Tantry, US	1
Huber, K	1
Emanuelsson, BM; Ravnefjord, A; van Giezen, JJ; Weilitz, J	1
Harrison, P	1
Bernlochner, I; Sibbing, D	1
Burgess, S; Juergens, CP; Mallard, TA	1
Lincoff, AM; May, CH	1
Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L	1
Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D	1
Alström, U; Åsenblad, N; Becker, RC; Brandrup-Wognsen, G; Cannon, CP; Held, C; Hogue, CW; Horrow, J; James, S; Mahaffey, KW; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L	1
DiNicolantonio, JJ; Serebruany, VL	6
Kastrati, A	1
Cattaneo, M; Faioni, EM	1
Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A	1
Akerblom, A; Asenblad, N; Becker, RC; Budaj, A; Claeys, MJ; Horrow, J; Husted, S; James, SK; Katus, H; Siegbahn, A; Storey, RF; Wallentin, L	1
Bennett, MR	1
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A	1
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A	1
Kiss, RG	1
Butler, K; Maya, J; Teng, R	1
Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L	1
Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M	1
Clemmensen, P; Dridi, NP; Holmvang, L	1
Aronow, WS	1
Armstrong, PW; Westerhout, CM	1
Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H	1
Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S	1
Asseburg, C; Giannitsis, E; Katus, H; Theidel, U	1
Hauge, J; Kragh, R; Poulsen, BK	1
Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I	1
Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C	1
Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US	1
Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L	1
Stiefelhagen, P	1
Wang, H; Wang, WE; Wang, X; Zeng, C	1
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K	1
Coleman, CI; Limone, BL	1
Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S	1
Oprea, AD; Popescu, WM	1
Biondi-Zoccai, G; Dinicolantonio, JJ	1
Enar, R	1
Göddertz, R	1
Huber, K; Lip, GY	1
Wheatcroft, S	1
Berger, JS	1
Dixon, T; Freeman, WD; Hanel, RA; Johns, G; Miller, DA; Navarro, R; Nordeen, JD; Sapin, M; Taussky, P; Tawk, RG	1
Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM	1
Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L	1
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL	1
Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C	1
Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D	1
Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM	1
Biondi-Zoccai, G; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Niazi, AK; Tomek, A	1
Dinicolantonio, JJ; Norgard, NB	1
Aylward, PE; Sinhal, AR	1
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Moertl, D; Steiner, S	1
Grove, EL; Würtz, M	2
Chua, D; Nishi, C	1
Curkovic, I; Egbring, M; Kullak-Ublick, GA	1
Gasche, D; Greiner, RA; Meier, B; Ulle, T	1
Ecob, R; Hossain, R; Joshi, RR; Judge, HM; Karunakaran, A; Morton, AC; Storey, RF; Wales, C; Walker, JV	1
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD	1
DiNicolantonio, JJ; Tomek, A	1
Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J	1
Adsett, G; Jayasinghe, R; Markham, R	1
Bansilal, S; Bonaca, MP; Sabatine, MS	1
Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H	1
Becker, RC; Cannon, CP; Cornel, JH; Giannitsis, E; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lindholm, D; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L; Wernroth, L	1
Campbell, CL; Moliterno, DJ	1
Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q	1
DiNicolantonio, JJ; Serebruany, VL; Sibbing, D	1
Cohen, D	1
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE	1
Horowitz, JD; Karnon, JD; Pekarsky, B; Sorich, MJ; Sorich, W; Wiese, MD	1
Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F	1
Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I	1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C	1
Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R	1
Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D	1
Hirschl, MM	1
Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J	1
Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H	1
Gupta, K; Singh, D; Vacek, JL	1
Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Kitrou, P; Pastromas, G; Siablis, D; Spiliopoulos, S	1
Francis, SE; Judge, HM; Steiner, T; Storey, RF; West, LE	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US	1
Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C	1
Sabouret, P; Taiel-Sartral, M	1
Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L	1
Blondeau, M; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Marquis, JF; Maze, R; Moudgil, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY	1
Caldeira, D; Ferreira, JJ; Pinto, FJ	1
Bouatou, Y; Gabrielli, A; Saudan, P	1
Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D	1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU	1
Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L	1
Taylor, J	1
Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D	1
Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW	1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P	1
Elosua, R; Marrugat, J; Vila, J	1
Daiber, A; Gori, T; Jurk, K; König, J; Krahn, U; Lackner, K; Munzel, T; Schnorbus, B; Warnke, S	1
Fortmann, SD; Serebruany, VL	2
Massberg, S; Sibbing, D	1
Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L	1
Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S	1
Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM	1
Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P	1
Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B	1
Maggioni, AP	1
Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI	1
Drucker, AG; Januzzi, JL; Manchette, AM	1
Emanuelsson, H; Hiasa, Y; Teng, R	1
Schühlen, H	1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI	1
Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L	1
Delle Karth, G; Siller-Matula, JM	1
Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y	1
Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E	1
Gaglia, MA	1
Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU	1
Adlam, D; Choudhury, RP; Hadley, G; Harrison, P	1
Ge, J; Qian, J; Wang, Q; Wu, H; Zhou, J	1
Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P	1
Baradat, C; Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Collet, JP; Ecollan, P; Goodman, SG; Hamm, CW; Hammett, CJ; Heutz, WM; Huber, K; Janzon, M; Lapostolle, F; Lassen, JF; Licour, M; Merkely, B; Montalescot, G; Silvain, J; Stibbe, O; Storey, RF; Swahn, E; Tsatsaris, A; van 't Hof, AW; Vicaut, E; Willems, FF; Zeymer, U	1
Fauchère, I; Schreiber, P; Wyss, C	1
Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L	1
Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L	1
Vengoechea, F	1
Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Lee, JY; Park, MK; Park, TH; Yi, SJ	1
Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R	1
Agostoni, P; Stella, PR; Timmers, L	1
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM	1
Anselmi, CV; Bacci, M; Mendolicchio, GL; Quagliuolo, V; Rota, LL; Roveda, M; Ruggeri, ZM; Zavalloni, D	1
Al-Turbak, H; Hibbert, B; Le May, MR; Moudgil, R; Osborne, C; So, DY	1
Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H	1
Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P	1
Anstrom, KJ; Bagai, A; Cohen, DJ; Effron, MB; Goodman, SG; Gupta, A; Honeycutt, E; Messenger, JC; Peterson, ED; Wang, TY	1
Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG	1
Cavallini, C; De Servi, S; Ferlini, M; Leonardi, S	1
Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K	1
Cho, JH; Ihm, CG; Jeong, KH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS	1
Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L	1
Jiang, M; You, JH	3
Roffman, DS	1
Anstrom, KJ; Cannon, CP; Cowper, PA; Davidson-Ray, L; Harrington, RA; Janzon, M; Kaul, P; Levin, LÅ; Mark, DB; Nikolic, E; Pan, W; Wallentin, L	1
Hlatky, MA; Kazi, DS	1
Akinosoglou, K; Alexopoulos, D; Barampoutis, N; Hahalis, G; Karvounis, H; Koniari, I; Panagiotidis, T; Patsilinakos, S; Perperis, A; Xanthopoulou, I; Ziakas, A	1
Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R	1
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S	1
Steg, PG; Wiviott, SD	1
Arnaud, L; Bonello, L; Cointe, S; Dignat-George, F; Frere, C; Guieu, R; Kerbaul, F; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Sabatier, F; Thuny, F	1
Heitmeier, S; Laux, V; Perzborn, E	1
Bednar, F; Knot, J; Maly, M; Motovska, Z; Ondrakova, M; Ulman, J	1
Aires, D; Deibert, B; Fischer, R; Fraga, G; Gillihan, R; Gollub, S; Laarman, R; Maybrook, RJ	1
Biasco, L; Clemmensen, P; De Backer, O; Engstrøm, T; Helqvist, S; Holmvang, L; Jørgensen, E; Kelbaek, H; Olivecrona, G; Pedersen, F; Ratcovich, H; Saunamäki, K; Tilsted, HH	1
Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ	1
Calcagno, S; Cavallo, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Placentino, F; Sardella, G; Stio, RE	1
Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM	1
Cherepanov, V; Kim, MH; Serebruany, VL; Tomek, A	1
Birnbaum, GD; Birnbaum, Y; Nanhwan, MK; Nylander, S; Perez-Polo, JR; Ye, Y	1
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M	1
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M	6
Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL	1
Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ	1
Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW	1
Chua, T; Gruntowicz, D; Johnson, SG; Morlock, RJ	1
Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S	1
Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R	1
Bouatou, Y; Daali, Y; Desmeules, J; Fontana, P; Samer, CF	1
Guimarães, PO; Tricoci, P	1
Chong, AY; Qutub, MA; So, DY	1
Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M	1
Bhatt, DL; Bonaca, MP; Braunwald, E; Collet, JP; Costa, F; Kereiakes, DJ; Lee, CW; Lincoff, AM; Mauri, L; Montalescot, G; Park, SJ; Sabatine, MS; Udell, JA; Valgimigli, M	1
Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T	1
Åberg, B; Barbu, M; Bjursten, H; Dreifaldt, M; Hansson, EC; Holmgren, A; Ivert, T; Jeppsson, A; Jidéus, L; Nozohoor, S; Svedjeholm, R	1
Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J	1
Bednar, F; Kopa, M; Kroupa, J; Motovska, Z; Ondrakova, M; Osmancik, P	1
Cao, A; Chen, T; Li, P; Liu, J; Liu, Y; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X	1
Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ	1
Al Khalifa, A; Al Shouli, S; Bonneau, C; Chung, J; Currie, ME; Fagan, A; Lee, MM; Mewhort, HE; Ruel, M; Teoh, H; Verma, S; White, CW; Yamashita, MH; Yanagawa, B	1
Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R	1
Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L	1
O'Donoghue, ML; Sarma, A	1
Kim, MH; Pokov, AN; Serebruany, VL; Tomek, A	1
Ajjan, RA; Dockrell, DH; Ecob, R; Faulkner, RE; Judge, HM; Khan, H; Outteridge, SN; Phoenix, F; Sabroe, I; Sangha, GK; Storey, RF; Thomas, MR; West, LE	1
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M	2
Giusti, B; Grifoni, E; Marcucci, R	1
Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Suryapranata, H; Verdoia, M	1
Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X	1
Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M	1
Abtan, J; Amour, J; Barthélémy, O; Brugier, D; Collet, JP; Kerneis, M; Leprince, P; Martin, R; Mercadier, A; Montalescot, G; O'Connor, SA; Silvain, J	1
Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL	1
Sachdeva, A	1
Bougouin, W; Cariou, A; Dumas, F; Gouffran, G; Jakamy, R; Joffre, J; Lamhaut, L; Rosencher, J; Varenne, O	1
Croce, KJ; Falcão, FC; Falcão, JL; Lemos, PA; Medeiros, F; Mont'Alverne-Filho, JR; Nicolau, JC; Rodrigues-Sobrinho, CR; Serruys, PW; Silva, RC; Valgimigli, M	1
Dobesh, PP; Doyle, M; Varnado, S	1
Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Traby, L; Wolzt, M	1
Fu, Q; Huang, YJ; Zhang, N; Zhang, Q; Zhu, K	1
Bai, J; Han, Q; Huang, XH; Liu, C; Shen, DL; Wang, B; Zhang, JY	1
Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY	1
Chava, S; Schneider, DJ	1
Alexopoulos, D; Barampoutis, N; Davlouros, P; Gkizas, V; Hahalis, G; Karanikas, S; Karvounis, H; Kontoprias, K; Koutsogiannis, N; Patsilinakos, S; Tsigkas, G; Xanthopoulou, I; Ziakas, A	1
Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L	1
Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M	1
Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weber, S; Zhou, Q	1
Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM	1
Abtan, J; Angiolillo, DJ; Ardissino, D; Gabriel Steg, P; Harrington, RA; Hellkamp, A; Himmelmann, A; Husted, S; James, SK; Katus, HA; Meier, B; Schulte, PJ; Storey, RF; Velders, MA; Wallentin, L	1
Bernat, I; Dragounová, E; Hromádka, M; Jirouš, Š; Pechman, V; Rokyta, R; Seidlerová, J; Tůmová, P	1
Parker, WA; Storey, RF	1
Li, Y; Li, Z; Miao, W; Su, G; Zhang, T	1
Barbieri, L; Bellomo, G; Daffara, V; Luca, GD; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M	1
Angiolillo, DJ; Carlson, G; Franchi, F; Khan, N; Mehran, R; Raveendran, G; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y	1
Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB	1
Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M	1
Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX	1
Angiolillo, DJ; Capodanno, D	1
Tang, N; Yin, SY	1
Arbel, Y; Lev, EI; Mosseri, M; Musallam, A; Orvin, K; Perl, L; Roguin, A	1
Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, I; Pentara, I; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I	1
Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R	1
Deliargyris, EN; Fan, W; Plent, S; Prats, J	1
Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P	1
Thachil, J	1
Chen, KY; Li, G; Liu, T; Xu, G; Zhang, N; Zhao, J	1
Ruiz-Nodar, JM	1
Biscaglia, S; Campo, G; Ferrari, R; Pavasini, R; Tebaldi, M; Tumscitz, C	1
Jain, N; Reilly, RF	1
De Luca, G; Verdoia, M	1
Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J	1
Ahn, TH; Ahn, Y; Cha, KS; Chae, JK; Chae, SC; Choi, DJ; Gwon, HC; Hwang, KK; Jeong, MH; Kim, HS; Kim, KB; Kim, YJ; Oh, DJ; Oh, SK; Park, KH; Seong, IW; Seung, KB	1
Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W	1
Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A	1
Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A	1
de Mol, BA; Li, WW; Manshanden, JS; Schotborgh, MA; Tomšič, A	1
Berbis, J; Bonello, L; Dignat-George, F; Frere, C; Kerbaul, F; Laine, M; Lemesle, G; Paganelli, F; Roch, A; Thuny, F	1
Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C	2
Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY	1
Blackman, D; Curzen, N; Dalby, M; Flather, M; Gershlick, AH; Greenwood, JP; Hetherington, S; Kelly, DJ; Khan, JN; Lai, FY; McCann, GP; Nazir, SA; Peebles, C; Swanton, H; Wong, J	1
Cotton, JM; Cox, AR; Khan, N	1
Bernlochner, I; Gross, L; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Orban, M; Rössner, L; Sibbing, D	1
Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S	1
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD	1
Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY	1
Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D	1
Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC	1
Aksakal, E	1
French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S	1
Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME	1
Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL	1
Caiazzo, G; Carino, A; De Rosa, S; Filippis, C; Indolfi, C; Mongiardo, A; Polimeni, A; Sabatino, J; Sorrentino, S; Spaccarotella, C; Strangio, A; Torella, D	1
Cattaneo, M; Cipriani, M; Femia, EA; Frigerio, M; Morici, N; Oliva, F; Perna, E	1
Khan, N	1
Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L	1
Ahn, JM; Chang, M; Kang, SJ; Kim, YH; Lee, CW; Lee, HS; Lee, SW; Moon, DH; Oh, M; Park, DW; Park, SJ; Park, SW	1
Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME	1
Cattabiani, MA; Di Vito, L; Gatto, L; Limbruno, U; Marco, V; Micari, A; Pawlowski, T; Prati, F; Romagnoli, E; Trivisonno, A; Versaci, F	1
Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M	1
Cheng, Q; Coelho, PG; Cronstein, BN; Mediero, A; Reddy, VS; Tovar, N; Whatling, C; Wilder, T; Witek, L	1
Barbieri, L; Bellomo, G; Daffara, V; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M	1
Cai, Q; Chen, L; Gao, L; Gu, Y; Li, P; Liu, J; Ma, L; Qin, Y; Wang, Z; Yang, Y; Zhao, X	1
Althouse, AD; Conrad Smith, AJ; Khandhar, SJ; Kudaravalli, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Schindler, JT; Sharbaugh, MS; Toma, C	1
Bhat, A; Pang, M; Wu, Y; Zhang, H; Zhang, Y; Zhao, Y; Zhuang, K	1
Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I	1
Barbato, E; Colaiori, I; Di Sciascio, G; Lauria Pantano, A; Mangiacapra, F; Panaioli, E; Pozzilli, P; Ricottini, E	1
Andersson, TL; Carlson, GF; Nylander, S; Teng, R	1
Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R	1
Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A	1
Baek, YS; Kim, DH; Kwan, J; Kwon, SW; Lee, MJ; Park, KS; Park, SD; Shin, SH; Woo, SI	1
Gurbel, PA; Kubica, J; Myat, A; Tantry, US	1
Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G	1
Brice, AE; Haynick, M; Hernandez, GA; Mendoza, CE; Sanchez, M	1
Badimon, L; Capdevila, A; Carlsson, L; Carreras, F; Casani, L; Gutiérrez, M; Hidalgo, A; Pons-Lladó, G; Varela, L; Vilahur, G	1
Cheema, AN; Cieza, T; Dehghani, P; Déry, JP; Fisher, HN; Goodman, SG; Henderson, MA; Kokis, A; Lavi, S; Lutchmedial, S; Mehta, SR; Siega, AJ; Welsh, RC; Wong, BY; Zhang, X; Zhu, YE	1
Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC	1
Baumgartner, I; Berger, JS; Blomster, J; Conte, MS; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C; White, CJ	1
Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL	1
Bagai, A; Brass, N; Cheema, AN; Dehghani, P; Dery, JP; Ducas, J; Fisher, HN; Fung, A; Goodman, SG; Kassam, SA; Kim, HH; Mehta, SR; Quraishi, AU; Schampaert, E; Wang, TY; Welsh, RC; Zhang, X; Zhu, YE	1
Bian, S; Dong, P; Yang, X	1
Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Henry, TD; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, ME	1
Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C	1
Blinc, A; Fister, M; Mijovski, MB; Mikuz, U; Noc, M; Steblovnik, K	1
Franchi, F; Rollini, F	1
Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM	3
Akhmedov, A; Beer, JH; Bonetti, NR; Camici, GG; Gaul, DS; Glanzmann, M; Keller, S; Lüscher, TF; Matter, CM; Reiner, MF; Ruf, W; Savarese, G; Stivala, S; Yang, Z; Zhu, C	1
Chen, J; Li, X; Lv, Q; Wang, Q; Xue, Y	1
Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J	1
Amstalden, H; Beer, JH; Benussi, S; Bonetti, NR; Breitenstein, A; Camici, GG; Falk, V; Glanzmann, M; Holy, EW; Keller, S; Lüscher, TF; Maisano, F; Reiner, MF; Savarese, G; Stämpfli, SF; Steffel, J	1
Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC	1
Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I	1
Chen, N; Ding, P; Liu, H; Wei, Y	1
Barbour, C; Gesheff, T	1
Angiolillo, DJ; Gaglia, MA; Kiramijyan, S; Lhermusier, T; Lipinski, MJ; Pokharel, S; Steinvil, A; Storey, RF; Torguson, R; Waksman, R; Wallentin, L	1
Hu, D; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Yu, T; Zhang, L; Zhang, X	1
Chan, R; Kong, SL; Kwok, J; Lee, S; Shea, C; Siu, D; Tam, CC; Tang, WH; Wong, A; Yung, A	1
Andrea, R; Brugaletta, S; Caixal, G; Flores-Umanzor, E; Freixa, X; Garcia, J; Hernandez-Enriquez, M; Jiménez-Brítez, G; Martin, V; Masotti, M; Regueiro, A; Sabaté, M; San Antonio, R	1
Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M	1
Cui, JG; Huang, XH; Liu, G; Lu, J; Wu, X; Zhao, XY; Zheng, XX	1
Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J	1
Aquila, G; Balla, C; Biscaglia, S; Campo, G; Cimaglia, P; Contoli, M; Del Franco, A; Ferrari, R; Fortini, F; Gallo, F; Pavasini, R; Pecoraro, A; Pestelli, G; Rizzo, P; Tonet, E; Vieceli Dalla Sega, F	1
Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS	1
Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y	1
Kanic, V; Kanic, Z; Kompara, G; Markota, A; Penko, M; Vollrath, M	1
Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X	1
Boasi, V; Cattunar, S; Mascelli, G; Perri, D; Pistis, G; Sànchez, FA; Secco, GG; Tacchi, C; Vercellino, M	1
Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J	1
Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L	1
Adeeb, N; Alturki, A; Foreman, PM; Griessenauer, CJ; Harrigan, MR; Levy, EI; Moore, JM; Motiei-Langroudi, R; Ogilvy, CS; Shallwani, H; Siddiqui, AH; Thomas, AJ	1
Dixon, SR; Gurm, HS; Khandelwal, A; LaLonde, TA; Seth, M; Sukul, D	1
Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Panzer, S; Pultar, J; Seidinger, D; Wadowski, PP	1
Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M	1
Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K	1
Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L	1
Adeeb, N; Griessenauer, CJ; Gupta, R; Moore, JM; Ogilvy, CS; Patel, AS; Shallwani, H; Siddiqui, A; Thomas, AJ; Youn, R	1
Chang, KS; Hong, YJ; Jeong, MH; Kim, HK; Kim, JH; Kim, MC; Kim, SS; Lim, HC; Lim, KS; Park, KH	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V	1
Cai, Y; Chen, S; Du, C; Gao, Y; Lai, W; Qin, C; Yang, C; Zhou, J	1
Aldazabal, A; Cerrato, E; Echavarría-Pinto, M; Escaned, J; Fernández-Ortiz, A; Gonzalo, N; Jimenez-Quevedo, P; Macaya, C; Mejia-Renteria, H; Nombela-Franco, L; Núñez-Gil, IJ; Quirós, A; Rumoroso, JR; Ryan, N; Salinas, P	1
Godier, A; Houssany-Pissot, S; Martin, AC; Taylor, G; Zlotnik, D	1
Choi, KN; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Park, YA; Seo, JS; Shin, HC; Yang, TH	1
Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO	1
Becker, RC; Cannon, CP; Davoudi, F; Diercks, DB; Himmelmann, A; James, SK; Lim, ST; Pollack, CV; Schulte, PJ; Spinar, J; Steg, PG; Storey, RF; Wallentin, L	1
Giedraitiene, A; Kupstyte, N; Lesauskaite, V; Tatarunas, V; Zaliunas, R	1
Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L	1
Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y	1
Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R	1
Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC	1
Christoph, M; Ende, G; Ibrahim, K; Jellinghaus, S; Loehn, T; Mierke, J; Pfluecke, C; Poitz, DM; Quick, S; Richter, B; Schoener, L; Speiser, U; Strasser, RH	1
Angiolillo, DJ; Cavallari, LH; Franchi, F; Kureti, M; Moon, JY; Rivas Rios, JR; Rollini, F	1
de Mast, Q; El Messaoudi, S; Gerretsen, J; Gomes, M; Kiers, D; Kox, M; Pickkers, P; Riksen, NP; Rongen, GA; van der Heijden, WA; van der Ven, AJ; van Ede, L	1
Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL	1
Budaj, A; Ramotowski, B; Żuk, A	1
Eipeldauer, M; Hobl, EL; Litschauer, B; Weisshaar, S; Wolzt, M	1
Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y	1
Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N	1
Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J	1
Giedraitiene, A; Jakstas, V; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V; Zvikas, V	1
Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J	1
Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I	1
Baber, U; Badimon, JJ; Contreras, J; Escolar, G; Fuster, V; Linares-Koloffon, CA; Mehran, R; Rey-Mendoza, J; Sartori, S; Smith, DA; Zafar, MU	1
Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U	1
Bash, LD; Patel, MD; Simpson, RJ; Vyas, A	1
Fairley, S; Harding, SA; Holley, A; Larsen, PD; Simmonds, M; Wilkins, B	1
Grove, EL; Hvas, AM; Kristensen, SD; Larsen, ML; Pedersen, OH	1
Han, Y; Li, C; Li, J; Li, Y; Qi, J; Tang, Y; Wang, H	1
Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Zimmermann, RH	1
Cattabiani, MA; De Palma, R; Guastaroba, P; Marino, M; Menozzi, A; Rasia, M; Solinas, E; Tadonio, I; Vignali, L	1
Cai, WY; Yang, J; Zeng, P	1
Dudek, D; Dziewierz, A; Kleczyński, P; Plens, K; Rakowski, T; Siudak, Z	1
Carugo, S; Castini, D; Cazzaniga, S; Centola, M; Ferrante, G; Lucreziotti, S; Persampieri, S; Salerno-Uriarte, D; Sponzilli, C	1
de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P	1
Bagai, A; Booker, J; Cantor, WJ; Cheema, AN; Crawford, JJ; Dehghani, P; Goodman, SG; Harenberg, S; Kelly, S; Lavi, S; Lavoie, A; Mehta, SR; Pon, Q; Yang, A; Zimmermann, RH	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C	1
He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z	1
Alves, CMR; Berwanger, O; Bianco, HT; Caixeta, A; Carvalho, ACC; Damiani, LP; Fonseca, FAH; Fonseca, HA; França, CN; Izar, MC; Klassen, A; Maugeri, IML; Moreira, FT; Pinto, IM; Soriano Lopes, A; Szarf, G; Tavares, MFM	1
Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM	1
Berthe, A; Diaby, V; Ezendu, K; Okere, AN	1
Hess, S; Jesel, L; Kibler, M; Marchandot, B; Messas, N; Meyer, N; Morel, O; Ohlmann, P; Ristorto, J; Schaeffer, M; Tuzin, N	1
Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Gallo, P; Granatelli, A; Gulizia, MM; Musumeci, G; Pennacchi, M; Rigattieri, S	1
He, B; Liu, Y; Tobe, RG; Wu, B	1
Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, G; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S	1
Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, C; Kim, JS; Ko, YG	1
Bai, J; Fu, Q; Gao, CZ; Liu, R; Ma, QQ; Wang, F; Wei, P; Wu, J; Yang, XJ	1
Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM	1
Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A	1
Guan, W; Lu, H; Yang, K	1
Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP	1
Daiber, A; Gori, T; Jurk, K; Koenig, J; Lackner, KJ; Münzel, T; Schnorbus, B; Warnke, S	1
Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y	1
Aranganathan, P; Balasundaram, R; Boopathi, A; Rangan, A; Wilson, B	1
Altun, S; Çetinbaş, A; Okur, Mİ; Özercan, İ; Öztan, M; Yıldız Altun, A	1
Dong, Z; Pan, L; Zhai, H; Zhang, B	1
Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S	1
Bliden, KP; Dahlen, J; Fisher, R; Gurbel, PA; Speros, PC; Sukavaneshvar, S; Tantry, US	1
Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U	1
Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z	1
Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM	1
DE Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Rognoni, A; Suryapranata, H; Verdoia, M	1
Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y	1
Li, X; Lv, Q; Wang, Z; Xu, S; Yao, Y	1
Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH	1
Arthur, JM; Arulprakash, N; Corken, A; Dai, J; Davis, O; Hedayati, SS; Jain, N; Mehta, JL; Phadnis, MA; Rahmatallah, Y; Smyth, S; Ware, J	1
Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS	1

Reviews

156 review(s) available for clopidogrel and adenosine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
The medicinal chemistry of the P2 receptor family. Progress in medicinal chemistry, 2001, Volume: 38 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriosclerosis; Cloning, Molecular; Clopidogrel; Cystic Fibrosis; Humans; Ophthalmic Solutions; Polyphosphates; Receptors, Purinergic P2; Structure-Activity Relationship; Ticlopidine; Tissue Distribution; Uracil Nucleotides	2001
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2005, Volume: 6, Issue:9 Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine; Time Factors; Vasodilator Agents	2005
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2006
Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine	2007
Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovascular drug reviews, 2007,Summer, Volume: 25, Issue:2 Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2007
ADP receptor antagonism: what's in the pipeline? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2007
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2008
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2009
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2009
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovascular therapeutics, 2009,Winter, Volume: 27, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction	2009
Advances in antiplatelet treatment for acute coronary syndromes. Heart (British Cardiac Society), 2010, Volume: 96, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor	2010
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2010
State of the art of new P2Y12 antagonists. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2010
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics. Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:3 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2010
The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine	2010
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2010
The year in interventional cardiology. Journal of the American College of Cardiology, 2010, May-18, Volume: 55, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome	2010
What goes into a major acute coronary syndrome trial and what will future trials look like? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom	2010
New antithrombotic agents--insights from clinical trials. Nature reviews. Cardiology, 2010, Volume: 7, Issue:9 Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine	2010
[Antiplatelet therapy in coronary heart disease. Some problems and achivements]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine	2010
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood, 2011, Feb-17, Volume: 117, Issue:7 Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine	2011
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vascular health and risk management, 2010, Oct-21, Volume: 6 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor: a novel oral antiplatelet agent. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2010, Volume: 25, Issue:11 Topics: Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Approval; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2010
Ticagrelor: from discovery to Phase III clinical trial. Future cardiology, 2010, Volume: 6, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
[Coronary heart disease - what is of importance after coronary intervention?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:5 Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2011
[Current options to manage clopidogrel poor responsiveness]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Recenti progressi in medicina, 2011, Volume: 102, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2011
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation). Current atherosclerosis reports, 2011, Volume: 13, Issue:4 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European heart journal, 2011, Volume: 32, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2011
Ticagrelor for acute coronary syndrome? Drug and therapeutics bulletin, 2011, Volume: 49, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2011
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists. Current cardiology reports, 2011, Volume: 13, Issue:5 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. Medizinische Monatsschrift fur Pharmazeuten, 2011, Volume: 34, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2011
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current medical research and opinion, 2011, Volume: 27, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Antiplatelet options for secondary prevention in acute coronary syndromes. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia	2011
Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes. Postgraduate medicine, 2011, Volume: 123, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Drug Interactions; Genotype; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine	2011
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current medical research and opinion, 2012, Volume: 28, Issue:2 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
P2Y12 platelet inhibition in clinical practice. Journal of thrombosis and thrombolysis, 2012, Volume: 33, Issue:2 Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2012
Unstable angina and non-ST elevation myocardial infarction. American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
InforMatrix: ADP antagonists in acute coronary syndromes. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International journal of cardiology, 2012, Jul-12, Volume: 158, Issue:2 Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery. Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine	2012
Current antiplatelet options for NSTE-ACS patients. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clinical pharmacokinetics, 2012, Jul-01, Volume: 51, Issue:7 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
[New antithrombotic drugs]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7 Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
[Platelet function: new drugs, new assays : possible impacts on operative medicine?]. Der Anaesthesist, 2012, Volume: 61, Issue:6 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert review of clinical pharmacology, 2012, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Development and clinical use of prasugrel and ticagrelor. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Antiplatelet therapy beyond 2012: role of personalized medicine. Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:6 Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2012
Clopidogrel in coronary artery disease: update 2012. Advances in cardiology, 2012, Volume: 47 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Advances in the monitoring of anti-P2Y12 therapy. Platelets, 2012, Volume: 23, Issue:7 Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2012
Thienopyridines and other ADP-receptor antagonists. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2012
Review of ticagrelor in the management of acute coronary syndromes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2012
Safety profile and bleeding risk of ticagrelor compared with clopidogrel. Expert opinion on drug safety, 2012, Volume: 11, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine	2012
New anti-platelet agents: the end of resistance? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
Why does ticagrelor induce dyspnea? Thrombosis and haemostasis, 2012, Volume: 108, Issue:6 Topics: Adenosine; Clopidogrel; Dyspnea; Humans; Models, Biological; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sensory Receptor Cells; Ticagrelor; Ticlopidine	2012
A critical overview on ticagrelor in acute coronary syndromes. QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome	2013
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis. Acta physiologica (Oxford, England), 2013, Volume: 207, Issue:2 Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century; Humans; Muscle, Smooth; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y; Ticagrelor; Ticlopidine	2013
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
[Novel agents for antithrombotic therapy in cardiology]. Orvosi hetilap, 2012, Dec-23, Volume: 153, Issue:51 Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2012
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovascular drugs and therapy, 2013, Volume: 27, Issue:3 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European heart journal, 2013, Volume: 34, Issue:23 Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2013
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. The Canadian journal of cardiology, 2013, Volume: 29, Issue:9 Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:4 Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. The American journal of cardiology, 2013, Sep-01, Volume: 112, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2013
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:8 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions]. Ugeskrift for laeger, 2013, Sep-09, Volume: 175, Issue:37 Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2013
New antiplatelet agents for cardiovascular disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Nov-05, Volume: 185, Issue:16 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[Thrombocyte aggregation inhibitors: what are the risks?]. Praxis, 2013, Oct-02, Volume: 102, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2013
Use of antiplatelet agents in patients with atherosclerotic disease. Postgraduate medicine, 2013, Volume: 125, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Dual antiplatelet therapy -- management in general practice. Australian family physician, 2013, Volume: 42, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Ticagrelor for acute coronary syndromes. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine	2013
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology, 2014, Volume: 127, Issue:1 Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction	2014
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke, 2014, Volume: 45, Issue:2 Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases	2014
[Differentiated antiplatelet therapy for acute coronary syndromes]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. Thrombosis and haemostasis, 2014, Volume: 111, Issue:6 Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2014
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?]. Revue medicale suisse, 2014, Feb-26, Volume: 10, Issue:419 Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood, 2014, Jul-31, Volume: 124, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
[Dual platelet inhibitors in intensive care units]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2014, Volume: 109, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of medicine, 2014, Volume: 46, Issue:7 Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine	2014
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome]. Praxis, 2014, Sep-03, Volume: 103, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine	2015
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor. Journal of pharmacy practice, 2016, Volume: 29, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. The American journal of cardiology, 2015, Mar-15, Volume: 115, Issue:6 Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction. International journal of cardiology, 2015, Sep-15, Volume: 195 Topics: Adenosine; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Survival Analysis; Ticagrelor; Ticlopidine	2015
Practical experience with ticagrelor: an Australian and New Zealand perspective. Current medical research and opinion, 2015, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. American heart journal, 2015, Volume: 170, Issue:1 Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review. Current drug metabolism, 2015, Volume: 16, Issue:2 Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Kidney Failure, Chronic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015? The Canadian journal of cardiology, 2015, Volume: 31, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Antiplatelet therapy in acute coronary syndromes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European heart journal, 2016, Jan-21, Volume: 37, Issue:4 Topics: Adenosine; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Humans; Long-Term Care; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2016
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2016, Volume: 27, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Stents; Ticagrelor; Ticlopidine	2016
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Glomerular Filtration Rate; Hemorrhage; Humans; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Renal Insufficiency; Ticagrelor; Ticlopidine	2015
On-treatment platelet reactivity: State of the art and perspectives. Vascular pharmacology, 2016, Volume: 77 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine	2016
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6 Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors	2015
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor. Current pharmaceutical design, 2016, Volume: 22, Issue:13 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Transcatheter Aortic Valve Replacement	2016
Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of diabetes research, 2016, Volume: 2016 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart (British Cardiac Society), 2016, 05-15, Volume: 102, Issue:10 Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
Antiplatelet therapy - a summary for the general physicians. Clinical medicine (London, England), 2016, Volume: 16, Issue:2 Topics: Adenosine; Clopidogrel; General Practitioners; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2016
Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions. Seminars in dialysis, 2016, Volume: 29, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine	2016
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC. Cardiovascular interventions, 2016, 05-23, Volume: 9, Issue:10 Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Evidence-Based Medicine; Hirudins; Humans; Markov Chains; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recombinant Proteins; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Thrombosis research, 2016, Volume: 143 Topics: Adenosine; Administration, Oral; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2013, Volume: 41 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2013
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma? Journal of the American College of Cardiology, 2016, 09-13, Volume: 68, Issue:11 Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors	2016
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in experimental medicine and biology, 2017, Volume: 906 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Esomeprazole; Gastrointestinal Hemorrhage; Gene Expression; Humans; Hydrogen-Ion Concentration; Peptic Ulcer; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2017
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. Platelets, 2017, Volume: 28, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors	2016
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine	2016
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. American heart journal, 2016, Volume: 181 Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine	2016
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals. Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine	2017
[Management of the bleeding risk associated with antiplatelet agents]. La Revue de medecine interne, 2017, Volume: 38, Issue:7 Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine	2017
[Antiplatelet agents and transfusion]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine	2017
Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:2 Topics: Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Testing; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2018
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. Stroke, 2017, Volume: 48, Issue:9 Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure	2017
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease. South Dakota medicine : the journal of the South Dakota State Medical Association, 2016, Volume: 69, Issue:10 Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine	2016
Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017, Volume: 37, Issue:5 Topics: Adenosine; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007-2017). Medicine, 2018, Volume: 97, Issue:43 Topics: Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Ticagrelor; Ticlopidine	2018

Trials

158 trial(s) available for clopidogrel and adenosine

Article	Year
Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis and thrombosis : a journal of vascular biology, 1992, Volume: 12, Issue:4 Topics: Adenosine; Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adult; Binding Sites; Blood Platelets; Clopidogrel; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, Purinergic; Thionucleotides; Thrombin; Ticlopidine	1992
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European heart journal, 2006, Volume: 27, Issue:9 Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding Time; Clopidogrel; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Ticagrelor; Ticlopidine	2006
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri Journal of the American College of Cardiology, 2007, Nov-06, Volume: 50, Issue:19 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine	2007
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American heart journal, 2009, Volume: 157, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets, 2009, Volume: 20, Issue:5 Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Relationship, Drug; Humans; Integrin beta3; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine	2009
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 2009, Dec-22, Volume: 120, Issue:25 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (London, England), 2010, Jan-23, Volume: 375, Issue:9711 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2010
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation, 2010, Mar-16, Volume: 121, Issue:10 Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2010
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clinical cardiology, 2010, Volume: 33, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine	2010
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease. Current neurology and neuroscience reports, 2010, Volume: 10, Issue:1 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ischemia; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2010
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. Journal of the American College of Cardiology, 2010, Jul-13, Volume: 56, Issue:3 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine	2010
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. British journal of clinical pharmacology, 2010, Volume: 70, Issue:1 Topics: Adenosine; Adult; Clopidogrel; Dose-Response Relationship, Drug; Fasting; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2010
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European heart journal, 2010, Volume: 31, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2010, Sep-14, Volume: 122, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. Journal of the American College of Cardiology, 2010, Oct-26, Volume: 56, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation, 2010, Nov-23, Volume: 122, Issue:21 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2010
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circulation. Cardiovascular genetics, 2010, Volume: 3, Issue:6 Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Genotype; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2010
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology, 2010, Volume: 117, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2010
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr Journal of the American College of Cardiology, 2011, May-10, Volume: 57, Issue:19 Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ (Clinical research ed.), 2011, Jun-17, Volume: 342 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:9 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors	2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States	2011
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. American heart journal, 2011, Volume: 162, Issue:1 Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2011
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European heart journal, 2011, Volume: 32, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). The American journal of cardiology, 2011, Dec-01, Volume: 108, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxygen Consumption; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Respiratory Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European heart journal, 2011, Volume: 32, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clinical chemistry, 2012, Volume: 58, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I	2012
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation, 2012, Jan-24, Volume: 125, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine	2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation, 2012, Feb-28, Volume: 125, Issue:8 Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clinical pharmacokinetics, 2012, Jun-01, Volume: 51, Issue:6 Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Platelet Aggregation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2012
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012, Jul-10, Volume: 184, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T	2012
Lessons from platelet inhibition and patient outcomes. Current opinion in cardiology, 2012, Volume: 27, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States	2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation, 2012, Jun-12, Volume: 125, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine	2012
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European heart journal, 2013, Volume: 34, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. American heart journal, 2012, Volume: 164, Issue:1 Topics: Adenosine; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2012
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American heart journal, 2012, Volume: 164, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation. Cardiovascular quality and outcomes, 2012, Sep-01, Volume: 5, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2012
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. Journal of the American College of Cardiology, 2012, Oct-23, Volume: 60, Issue:17 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? Stroke, 2012, Volume: 43, Issue:12 Topics: Adenosine; Cerebrovascular Disorders; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2012
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. American heart journal, 2012, Volume: 164, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Analysis of Variance; Biomarkers; Clopidogrel; Cystatin C; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. Circulation, 2013, Feb-12, Volume: 127, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial. Journal of interventional cardiology, 2013, Volume: 26, Issue:3 Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors	2013
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes care, 2013, Volume: 36, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine	2013
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke, 2013, Volume: 44, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. The American journal of medicine, 2013, Volume: 126, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Quality of Life; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Time Factors	2013
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation, 2013, Sep-03, Volume: 128, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine	2013
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Swiss medical weekly, 2013, Volume: 143 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine	2013
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. Platelets, 2014, Volume: 25, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; United Kingdom	2014
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets, 2014, Volume: 25, Issue:7 Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Sepsis; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a Circulation, 2014, Jan-21, Volume: 129, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentiation Factor 15; Hospital Mortality; Humans; Kaplan-Meier Estimate; Myocardial Revascularization; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Troponin T	2014
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. Journal of the American College of Cardiology, 2014, Mar-11, Volume: 63, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, Liquid; Clopidogrel; Cyclic AMP; Erythrocytes; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2014
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2014, Volume: 46, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Ticlopidine	2014
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. Scandinavian cardiovascular journal : SCJ, 2014, Volume: 48, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Denmark; Humans; Purinergic P2Y Receptor Antagonists; Sweden; Ticagrelor; Ticlopidine	2014
A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PloS one, 2014, Volume: 9, Issue:3 Topics: Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ticagrelor; Ticlopidine	2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European heart journal, 2014, Jun-14, Volume: 35, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European heart journal, 2014, Aug-14, Volume: 35, Issue:31 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, control BMJ open, 2014, May-06, Volume: 4, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxidative Stress; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2014
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European journal of preventive cardiology, 2015, Volume: 22, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial. Trials, 2014, May-01, Volume: 15 Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography	2014
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovascular intervention and therapeutics, 2014, Volume: 29, Issue:4 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Young Adult	2014
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart (British Cardiac Society), 2014, Volume: 100, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cause of Death; Clopidogrel; Confidence Intervals; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors	2014
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thrombosis and haemostasis, 2014, Volume: 112, Issue:5 Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine	2014
Prehospital ticagrelor in ST-segment elevation myocardial infarction. The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11 Topics: Adenosine; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time-to-Treatment	2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart (British Cardiac Society), 2015, Volume: 101, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Brazil; Clopidogrel; Cost-Benefit Analysis; Disease Management; Electrocardiography; Female; Germany; Health Care Costs; Humans; Male; Markov Chains; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Sweden; Ticagrelor; Ticlopidine; United Kingdom	2015
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, Volume: 11, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1 Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Hispanic or Latino; Humans; Middle Aged; Platelet Activation; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia. The Canadian journal of cardiology, 2014, Volume: 30, Issue:11 Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Contemporary clinical trials, 2015, Volume: 40 Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Research Design; Ticagrelor; Ticlopidine; Warfarin; Young Adult	2015
Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties. International journal of cardiology, 2015, Feb-15, Volume: 181 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine	2015
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:6 Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Single-Blind Method; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion, 2015, Volume: 55, Issue:6 Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2015
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2015
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:3 Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Female; Fibrinolysis; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Prospective Studies; Ticagrelor; Ticlopidine	2015
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. International journal of cardiology, 2015, Volume: 187 Topics: Acute Coronary Syndrome; Adenosine; Aged; Antigens, CD34; Body Mass Index; Clopidogrel; Endothelial Progenitor Cells; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemporary clinical trials, 2015, Volume: 43 Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin	2015
Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. International journal of cardiology, 2015, Sep-01, Volume: 194 Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Genetic Variation; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American heart journal, 2015, Volume: 169, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2015
[Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2015, Jun-18, Volume: 47, Issue:3 Topics: Adenosine; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2015
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:7 Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. Journal of thrombosis and thrombolysis, 2016, Volume: 41, Issue:4 Topics: Adenosine; Aged; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Agonists; Ticagrelor; Ticlopidine	2016
Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Scientific reports, 2015, Sep-09, Volume: 5 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. Cardiovascular revascularization medicine : including molecular interventions, 2015, Volume: 16, Issue:8 Topics: Adenosine; Administration, Oral; Aged; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hispanic or Latino; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Regression Analysis; Risk Assessment; Severity of Illness Index; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2015
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, Oct-09, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:12 Topics: Adenosine; Anti-Inflammatory Agents; Biomarkers; Blood Platelets; Chemotaxis, Leukocyte; Clopidogrel; Cytokines; Endotoxins; England; Female; Fibrin Fibrinogen Degradation Products; Humans; Inflammation; Inflammation Mediators; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult	2015
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. American heart journal, 2015, Volume: 170, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Transplantation, Homologous; Treatment Outcome	2015
Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2016, Volume: 87, Issue:7 Topics: Adenosine; Aged; Angioplasty, Balloon, Coronary; Brazil; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; ST Elevation Myocardial Infarction; Thrombectomy; Ticagrelor; Ticlopidine; Time Factors; Time-to-Treatment; Treatment Outcome	2016
Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:2 Topics: Adenosine; Adolescent; Adult; Area Under Curve; Aspirin; Austria; beta-Thromboglobulin; Biomarkers; Bleeding Time; Blood Platelets; Clopidogrel; Double-Blind Method; Healthy Volunteers; Hemostasis; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prothrombin; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ROC Curve; Ticagrelor; Ticlopidine; Time Factors; Young Adult	2016
Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:23 Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison. Platelets, 2016, Volume: 27, Issue:5 Topics: Adenosine; Biomarkers; Blood Platelets; Clopidogrel; Electrocardiography; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine	2016
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. European heart journal, 2016, Sep-14, Volume: 37, Issue:35 Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine	2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart (British Cardiac Society), 2016, Volume: 102, Issue:8 Topics: Adenosine; Aged; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for Trials, 2016, Feb-11, Volume: 17 Topics: Adenosine; Biomarkers; C-Reactive Protein; CD40 Ligand; Clinical Protocols; Clopidogrel; Endothelium, Vascular; Humans; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sample Size; Ticagrelor; Ticlopidine	2016
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. Journal of the American College of Cardiology, 2016, Feb-16, Volume: 67, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Troponin	2016
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). The Canadian journal of cardiology, 2016, Volume: 32, Issue:10 Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Troponin	2016
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American heart journal, 2016, Volume: 174 Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2016
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:2 Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level. Journal of the American College of Cardiology, 2016, Apr-26, Volume: 67, Issue:16 Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2016
One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. International journal of cardiology, 2016, 07-15, Volume: 215 Topics: Adenosine; Aged; China; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? International journal of cardiology, 2016, Jul-15, Volume: 215 Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People	2016
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. American heart journal, 2016, Volume: 175 Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study. Journal of the American Heart Association, 2016, 05-31, Volume: 5, Issue:6 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Female; Humans; Magnetic Resonance Angiography; Male; Microvessels; Middle Aged; Myocardial Revascularization; Organ Size; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets, 2016, Volume: 27, Issue:8 Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American heart journal, 2016, Volume: 177 Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine	2016
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American heart journal, 2016, Volume: 177 Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2016
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Cardiovascular therapeutics, 2016, Volume: 34, Issue:5 Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2016
Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor. BioMed research international, 2016, Volume: 2016 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Substitution; Female; Gene Expression Regulation; Humans; Male; MicroRNAs; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2016
Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation. Clinical cardiology, 2016, Volume: 39, Issue:11 Topics: Adenosine; Aged; Anti-Inflammatory Agents; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Radiopharmaceuticals; Republic of Korea; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Journal of cardiovascular medicine (Hagerstown, Md.), 2016, Volume: 17, Issue:9 Topics: Abciximab; Adenosine; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Reperfusion; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombectomy; Thrombosis; Ticagrelor; Ticlopidine; Tomography, Optical Coherence	2016
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. American heart journal, 2016, Volume: 178 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors	2016
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. Acta cardiologica, 2016, Volume: 71, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Circulation, 2016, Sep-13, Volume: 134, Issue:11 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2016
Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:12 Topics: Adenosine; Adult; Blood Component Removal; Blood Platelets; Body Mass Index; Case-Control Studies; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Hemostasis; Humans; Male; Platelet Aggregation Inhibitors; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Ticagrelor; Ticlopidine; Time Factors; Young Adult	2016
Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2016, Oct-10, Volume: 12, Issue:8 Topics: Adenosine; Aged; Clopidogrel; Creatine Kinase; Echocardiography; Female; Humans; Male; Microvessels; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Severity of Illness Index; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Vascular Resistance	2016
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Administration Schedule; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Ontario; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 2017, Jan-17, Volume: 135, Issue:3 Topics: Adenosine; Aged; Clopidogrel; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. The New England journal of medicine, 2017, 01-05, Volume: 376, Issue:1 Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Leg; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2017
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. Medical science monitor : international medical journal of experimental and clinical research, 2016, Dec-15, Volume: 22 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study. Circulation, 2016, 12-20, Volume: 134, Issue:25 Topics: Activation, Metabolic; Adenosine; Clopidogrel; Coma; Humans; Hypothermia, Induced; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Resuscitation; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Randomized Comparison of Oral P2Y JACC. Cardiovascular interventions, 2017, 01-23, Volume: 10, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. The Journal of international medical research, 2017, Volume: 45, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Gene Frequency; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine	2017
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet (London, England), 2017, May-06, Volume: 389, Issue:10081 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thrombosis and haemostasis, 2017, 03-23, Volume: 117, Issue:6 Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytokines; Endothelium, Vascular; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nitric Oxide; Percutaneous Coronary Intervention; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Ticagrelor; Ticlopidine	2017
The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. International journal of cardiology, 2017, Jul-01, Volume: 238 Topics: Adenosine; Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine	2017
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design. International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:3 Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Heterozygote; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, Apr-14, Volume: 6, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation	2017
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. European heart journal, 2017, Nov-01, Volume: 38, Issue:41 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology. Cardiovascular diabetology, 2017, 05-19, Volume: 16, Issue:1 Topics: Adenosine; Blood Platelets; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Coronary Circulation; Diabetes Mellitus, Type 2; Humans; Microcirculation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Spain; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation	2017
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical cardiology, 2017, Volume: 40, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y Journal of thrombosis and thrombolysis, 2017, Volume: 44, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors	2017
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. Kardiologia polska, 2017, Volume: 75, Issue:9 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine	2017
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thrombosis and haemostasis, 2017, 08-30, Volume: 117, Issue:9 Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cytokines; Drug Therapy, Combination; Endotoxemia; Endotoxins; Healthy Volunteers; Humans; Inflammation; Inflammation Mediators; Male; Netherlands; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult	2017
Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study. British journal of clinical pharmacology, 2017, Volume: 83, Issue:12 Topics: Adenosine; Administration, Oral; Adolescent; Adult; Austria; Blood Flow Velocity; Clopidogrel; Drug Administration Schedule; Endothelium, Vascular; Forearm; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Regional Blood Flow; Reperfusion Injury; Single-Blind Method; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents; Young Adult	2017
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10 Topics: Adenosine; Aged; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. The New England journal of medicine, 2017, 10-19, Volume: 377, Issue:16 Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin	2017
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. British journal of clinical pharmacology, 2018, Volume: 84, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Elimination; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine; Treatment Outcome	2018
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. American heart journal, 2017, Volume: 192 Topics: Adenosine; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Preoperative Care; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors	2017
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:2 Topics: Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2018
Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute My Trials, 2017, Dec-19, Volume: 18, Issue:1 Topics: Adenosine; Anti-Inflammatory Agents; B-Lymphocytes; Biomarkers; Brazil; Clinical Protocols; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enzyme-Linked Immunospot Assay; Ezetimibe; Female; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Magnetic Resonance Imaging; Male; Metabolomics; Platelet Aggregation Inhibitors; Proteomics; Research Design; Rosuvastatin Calcium; Simvastatin; ST Elevation Myocardial Infarction; Stroke Volume; T-Lymphocytes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling	2017
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018, Volume: 55, Issue:1 Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome; Vascular Surgical Procedures	2018
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. JACC. Cardiovascular interventions, 2018, 08-27, Volume: 11, Issue:16 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Clopidogrel; Coronary Vessels; Cross-Over Studies; Endothelium, Vascular; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation	2018
Randomized Comparison of Strut Coverage between Ticagrelor and Clopidogrel in Acute Myocardial Infarction at 3-Month Optical Coherence Tomography. Yonsei medical journal, 2018, Volume: 59, Issue:5 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Neointima; Prospective Studies; Prostheses and Implants; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome	2018
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la Lancet (London, England), 2018, 09-15, Volume: 392, Issue:10151 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2018
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. European heart journal, 2020, 09-01, Volume: 41, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Vessels; Endothelium; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome	2020
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study). Platelets, 2022, Nov-17, Volume: 33, Issue:8 Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome	2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease. Journal of thrombosis and thrombolysis, 2022, Volume: 54, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor	2022
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascular pharmacology, 2023, Volume: 148 Topics: Adenosine; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2023
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023, Volume: 23, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2023

Other Studies

256 other study(ies) available for clopidogrel and adenosine

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets, 2004, Volume: 15, Issue:5 Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Postoperative Hemorrhage; Purinergic P2 Receptor Antagonists; Retrospective Studies; Thrombelastography; Ticlopidine; Time Factors	2004
Antiplatelet agents make a comeback in ST-elevation myocardial infarction. American heart journal, 2007, Volume: 154, Issue:4 Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2007
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. International journal of clinical practice, 2009, Volume: 63, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Test before you stop. Archives of surgery (Chicago, Ill. : 1960), 2009, Volume: 144, Issue:8 Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2009
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection	2009
Ticagrelor--is there need for a new player in the antiplatelet-therapy field? The New England journal of medicine, 2009, Sep-10, Volume: 361, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2009
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us? Nature reviews. Cardiology, 2009, Volume: 6, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Ticagrelor versus clopidogrel in acute coronary syndromes. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine	2009
The PLATO trial: do you believe in magic? European heart journal, 2010, Volume: 31, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2010
The TRITON versus PLATO trials: differences beyond platelet inhibition. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor versus clopidogrel in acute coronary syndromes. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine	2009
Ticagrelor versus clopidogrel in acute coronary syndromes. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine	2009
Ticagrelor versus clopidogrel in acute coronary syndromes. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Research Design; Ticagrelor; Ticlopidine	2009
Ticagrelor in ACS: redefining a new standard of care? Lancet (London, England), 2010, Jan-23, Volume: 375, Issue:9711 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2010
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study]. Kardiologiia, 2010, Volume: 50, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Circulation, 2010, Mar-16, Volume: 121, Issue:10 Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2010
Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test. Srpski arhiv za celokupno lekarstvo, 2010, Volume: 138 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Antithrombins; Aspirin; beta-Thromboglobulin; Blood Coagulation; Clopidogrel; Coronary Stenosis; Epinephrine; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Factor 4; Protein C; Ticlopidine; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents	2010
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thrombosis and haemostasis, 2010, Volume: 104, Issue:3 Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Disease Models, Animal; Dogs; Drug Therapy, Combination; Echocardiography; Female; Fibrinolytic Agents; Laser-Doppler Flowmetry; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Time Factors; Tissue Plasminogen Activator	2010
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine	2010
[The PLATO study]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine	2010
Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2010, Volume: 29, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Cyclic N-Oxides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Ticagrelor; Ticlopidine	2010
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European heart journal, 2010, Volume: 31, Issue:24 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2010
Emerging oral antiplatelet therapies for acute coronary syndromes. Hospital practice (1995), 2010, Volume: 38, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:4 Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Is ticagrelor the antiplatelet therapy panacea? Circulation. Cardiovascular genetics, 2010, Volume: 3, Issue:6 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology, 2011, Feb-08, Volume: 57, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine	2011
Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. Journal of the American College of Cardiology, 2011, Feb-08, Volume: 57, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2011
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials]. Annales de cardiologie et d'angeiologie, 2010, Volume: 59 Suppl 2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2010
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation, 2011, Feb-01, Volume: 123, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States	2011
Resistance to anti-platelet agents. Thrombosis research, 2011, Volume: 127 Suppl 3 Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thrombosis and haemostasis, 2011, Volume: 105, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Bias; Clinical Trials as Topic; Clopidogrel; Europe; Humans; Mortality; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2011
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. American heart journal, 2011, Volume: 161, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine	2011
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified Thrombosis and haemostasis, 2011, Volume: 105, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Epidemiologic Research Design; Europe; Humans; Patient Selection; Practice Guidelines as Topic; Statistics as Topic; Survival Analysis; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2011
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5) Thrombosis and haemostasis, 2011, Volume: 105, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clopidogrel; Europe; Genetic Predisposition to Disease; Humans; Research Design; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2011
[Do genetic factors reduce the effects of clopidogrel?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Non-interventional management of acute coronary syndromes. BMJ (Clinical research ed.), 2011, Jun-17, Volume: 342 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2011
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)? The Medical letter on drugs and therapeutics, 2011, Sep-05, Volume: 53, Issue:1372 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States	2011
The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. Cardiology, 2011, Volume: 119, Issue:2 Topics: Adenosine; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Drug-Eluting Stents; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2011
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor. Thrombosis and haemostasis, 2011, Volume: 106, Issue:6 Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelets; Clopidogrel; Cytoprotection; Platelet Activation; Protein Binding; Purinergic P2Y Receptor Antagonists; Rats; Rats, Inbred WKY; Thrombosis; Ticagrelor; Ticlopidine	2011
No free lunches: balancing bleeding and efficacy with ticagrelor. European heart journal, 2011, Volume: 32, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine	2011
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation. Circulation, 2012, Jan-24, Volume: 125, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2012
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment. Journal of cardiovascular medicine (Hagerstown, Md.), 2012, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thrombosis research, 2012, Volume: 130, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine	2012
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient? Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Feb-01, Volume: 79, Issue:2 Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent. Cardiology, 2011, Volume: 120, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Disclosure; Humans; Informed Consent; Multicenter Studies as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Research Support as Topic; Selection Bias; Ticagrelor; Ticlopidine; Treatment Refusal; United States; United States Food and Drug Administration	2011
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction]. Kardiologia polska, 2012, Volume: 70, Issue:2 Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2012
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction]. Kardiologia polska, 2012, Volume: 70, Issue:2 Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2012
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke. Circulation, 2012, Jun-12, Volume: 125, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine	2012
Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:2 Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine	2012
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets, 2012, Volume: 23, Issue:5 Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients? Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
Ticagrelor FDA approval issues revisited. Cardiology, 2012, Volume: 122, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2012
Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thrombosis research, 2012, Volume: 130, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Animals; Blood Platelets; Clopidogrel; Dogs; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2012
Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clinical cardiology, 2012, Volume: 35, Issue:11 Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Clopidogrel; Drug Interactions; Dyspnea; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Diseases; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2012
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets, 2013, Volume: 24, Issue:8 Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult	2013
Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? International journal of cardiology, 2013, May-25, Volume: 165, Issue:3 Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports. Therapeutic advances in cardiovascular disease, 2013, Volume: 7, Issue:1 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2013
The power of more than one. Circulation, 2013, Feb-12, Volume: 127, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2013
Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology, 2013, Volume: 124, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Simvastatin; Ticagrelor; Ticlopidine	2013
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thrombosis research, 2013, Volume: 131, Issue:4 Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Vascular Resistance	2013
[Gastrointestinal bleeding after treatment with ticagrelor]. Ugeskrift for laeger, 2013, Mar-11, Volume: 175, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Humans; Pulmonary Disease, Chronic Obstructive; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. Singapore medical journal, 2013, Volume: 54, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine	2013
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:4 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)]. MMW Fortschritte der Medizin, 2013, Feb-21, Volume: 155, Issue:3 Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology, 2013, Volume: 124, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2013
Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports. International journal of cardiology, 2013, Sep-30, Volume: 168, Issue:2 Topics: Adenosine; Clopidogrel; Drug-Eluting Stents; Humans; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2013
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)]. MMW Fortschritte der Medizin, 2013, Apr-18, Volume: 155, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States	2013
Is clopidogrel adequate in 2013? Cardiovascular journal of Africa, 2013, Volume: 24, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. Journal of neurointerventional surgery, 2014, Volume: 6, Issue:4 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cerebrovascular Disorders; Clopidogrel; Endovascular Procedures; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Retrospective Studies; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology, 2013, Volume: 126, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
P2Y12 Receptor Blockade and Myocardial Perfusion. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2013
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3 Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Incidence; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2013
Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. International journal of cardiology, 2013, Oct-30, Volume: 169, Issue:2 Topics: Adenosine; Advisory Committees; Clinical Trials as Topic; Clopidogrel; Contraindications; Drug Approval; Follow-Up Studies; Humans; Mortality; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome; Vital Statistics	2013
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. British journal of anaesthesia, 2014, Volume: 112, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine	2014
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes. Circulation, 2014, Jan-21, Volume: 129, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Revascularization; Ticagrelor; Ticlopidine	2014
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thrombosis and haemostasis, 2014, Volume: 111, Issue:2 Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
US lawyers investigate trial that secured license for AstraZeneca's antiplatelet drug. BMJ (Clinical research ed.), 2013, Nov-08, Volume: 347 Topics: Adenosine; Clopidogrel; Consumer Product Safety; Drug Approval; Drug Industry; Drug Therapy, Combination; Female; Humans; Licensure; Male; Public Health; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2013
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists. Thrombosis and haemostasis, 2014, Mar-03, Volume: 111, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine	2014
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics, 2013, Volume: 14, Issue:16 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Australia; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Markov Chains; Ticagrelor; Ticlopidine	2013
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. American heart journal, 2014, Volume: 167, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Ticagrelor as an alternative in clopidogrel-associated neutropenia. Platelets, 2015, Volume: 26, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Discrepancies in the primary PLATO trial publication and the FDA reviews. International journal of cardiology, 2014, Mar-01, Volume: 172, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Congresses as Topic; Humans; Information Dissemination; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2014
Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies. Cardiology, 2014, Volume: 127, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Reproducibility of Results; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Smoking status and the effects of antiplatelet drugs. BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor. Heart, lung & circulation, 2014, Volume: 23, Issue:4 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2014
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures. Cardiovascular and interventional radiology, 2014, Volume: 37, Issue:6 Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures; Female; Follow-Up Studies; Humans; Leg; Limb Salvage; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovascular research, 2014, Jun-01, Volume: 102, Issue:3 Topics: Adenosine; Animals; Apolipoproteins E; Atherosclerosis; Blood Platelets; Blood Vessels; Clopidogrel; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2014
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation, 2014, Volume: 85, Issue:5 Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Controversies in acute cardiovascular care. European heart journal, 2014, Volume: 35, Issue:9 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European heart journal, 2014, Jun-14, Volume: 35, Issue:23 Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases. Heart and vessels, 2015, Volume: 30, Issue:4 Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Is it appropriate to compare the results from two clinical trials with one drug in common? Revista espanola de cardiologia (English ed.), 2013, Volume: 66, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2013
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics". Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value. Thrombosis and haemostasis, 2014, Jul-03, Volume: 112, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2014
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. International journal of cardiology, 2014, Jul-01, Volume: 174, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results. Kardiologia polska, 2014, Volume: 72, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Models, Economic; Poland; Secondary Prevention; State Medicine; Ticagrelor; Ticlopidine	2014
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). British journal of clinical pharmacology, 2014, Volume: 77, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Administration Schedule; Humans; Medication Adherence; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2014
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?]. Giornale italiano di cardiologia (2006), 2014, Volume: 15, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan	2014
Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy. Pharmacotherapy, 2014, Volume: 34, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Clopidogrel; Drug Hypersensitivity; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine	2014
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed? European heart journal, 2014, Aug-14, Volume: 35, Issue:31 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2014
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9 Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation	2014
Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition? Heart (British Cardiac Society), 2014, Volume: 100, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Cause of Death; Clopidogrel; Female; Humans; Male; Ticagrelor; Ticlopidine	2014
Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry? BMJ case reports, 2014, Aug-12, Volume: 2014 Topics: Adenosine; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Short Bowel Syndrome; Ticagrelor; Ticlopidine	2014
First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea. International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3 Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Dyspnea; Humans; Male; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticagrelor; Ticlopidine	2014
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Jul-01, Volume: 38, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors	2014
Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets, 2015, Volume: 26, Issue:6 Topics: Adenosine; Adult; Asian People; Blood Platelets; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine; Young Adult	2015
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy. European heart journal, 2015, Feb-07, Volume: 36, Issue:6 Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine	2015
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ open, 2014, Oct-31, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. Thrombosis and haemostasis, 2015, Volume: 113, Issue:3 Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thrombosis research, 2015, Volume: 135, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin	2015
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. European heart journal. Acute cardiovascular care, 2015, Volume: 4, Issue:6 Topics: Adenosine; Aged; Clopidogrel; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC cardiovascular disorders, 2014, Dec-16, Volume: 14 Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine	2014
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Global heart, 2014, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization	2014
A delicate balance: the cost effectiveness of new antiplatelet agents. Journal of the American College of Cardiology, 2015, Feb-10, Volume: 65, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2015
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9 Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:6 Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban; Thrombin; Ticagrelor; Ticlopidine	2015
Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry. Thrombosis research, 2015, Volume: 135, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Drug Design; Female; Humans; Male; Middle Aged; Patient Admission; Percutaneous Coronary Intervention; Platelet Count; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Ticagrelor; Ticlopidine	2015
Ticagrelor-induced acute generalized exanthematous pustulosis. International journal of cardiology, 2015, Jul-15, Volume: 191 Topics: Acute Coronary Syndrome; Acute Generalized Exanthematous Pustulosis; Adenosine; Aged; Biopsy; Clopidogrel; Drug Eruptions; Female; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2015
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study. Thrombosis and haemostasis, 2015, Aug-31, Volume: 114, Issue:3 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Drug Administration Schedule; Emergency Medical Services; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:8 Topics: Adenosine; Administration, Oral; Animals; Apoptosis; Cardiotonic Agents; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Injections, Intraperitoneal; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Signal Transduction; Ticagrelor; Ticlopidine; Time Factors; Ventricular Function, Left; Ventricular Remodeling	2015
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. Journal of cardiovascular pharmacology, 2015, Volume: 66, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2015
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine	2015
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genetic Testing; Genotype; Humans; Managed Care Programs; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticagrelor; Ticlopidine	2015
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic? Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Conflict of Interest; Humans; Peer Review; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Selection Bias; Ticagrelor; Ticlopidine	2015
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine	2015
Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. European heart journal, 2016, Jan-07, Volume: 37, Issue:2 Topics: Adenosine; Aged; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Registries; Reoperation; Retrospective Studies; Sweden; Ticagrelor; Ticlopidine; Time Factors	2016
Dual antiplatelet therapy use by Canadian cardiac surgeons. The Journal of thoracic and cardiovascular surgery, 2015, Volume: 150, Issue:6 Topics: Adenosine; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ticagrelor; Ticlopidine	2015
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenetics and genomics, 2015, Volume: 25, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Blood Platelets; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Genotype; Health Care Costs; Heterozygote; Humans; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine	2015
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. Cardiovascular drugs and therapy, 2015, Volume: 29, Issue:5 Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine	2015
PHILO -- ensuring trial results are not lost in translation. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2015
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors	2016
Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascular pharmacology, 2016, Volume: 79 Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine	2016
Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. Atherosclerosis, 2015, Volume: 243, Issue:2 Topics: Adenosine; Aged; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polypharmacy; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. Herz, 2016, Volume: 41, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Female; Germany; Humans; Male; Non-ST Elevated Myocardial Infarction; Prevalence; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Current Antiplatelet Agents in Acute Coronary Syndrome. The Journal of the Association of Physicians of India, 2015, Volume: 63, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel? Resuscitation, 2016, Volume: 98 Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population. Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:3 Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. Clinical cardiology, 2016, Volume: 39, Issue:1 Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. Coronary artery disease, 2016, Volume: 27, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel. Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:1 Topics: Adenosine; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
Access-site bleeding and radial artery occlusion in transradial primary percutaneous coronary intervention: influence of adjunctive antiplatelet therapy. Coronary artery disease, 2016, Volume: 27, Issue:4 Topics: Abciximab; Adenosine; Aged; Antibodies, Monoclonal; Catheterization, Peripheral; Clopidogrel; Female; Hematoma; Hemorrhage; Hemostatic Techniques; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Punctures; Purinergic P2Y Receptor Antagonists; Radial Artery; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2016
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:4 Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrinogen; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Triglycerides; Uric Acid	2016
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Sex Characteristics; Ticagrelor; Ticlopidine	2016
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Internal medicine journal, 2016, Volume: 46, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs. Langmuir : the ACS journal of surfaces and colloids, 2016, Mar-22, Volume: 32, Issue:11 Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine	2016
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention]. Zhonghua xin xue guan bing za zhi, 2016, Volume: 44, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine	2016
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine	2016
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: comment. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:7 Topics: Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2016
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice. The American journal of cardiology, 2016, May-01, Volume: 117, Issue:9 Topics: Adenosine; Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Retrospective Studies; Ticagrelor; Ticlopidine; United States	2016
Another side effect of ticagrelor: Atrial fibrillation. International journal of cardiology, 2016, Jun-01, Volume: 212 Topics: Adenosine; Aged; Angina, Unstable; Atrial Fibrillation; Clopidogrel; Humans; Male; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors	2016
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. Platelets, 2016, Volume: 27, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angiography; Cause of Death; Clopidogrel; Comorbidity; Drug Substitution; Female; Health Care Surveys; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Risk Factors; Ticagrelor; Ticlopidine	2016
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. Cardiovascular therapeutics, 2016, Volume: 34, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation	2016
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: reply. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:7 Topics: Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2016
Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. International journal of cardiology, 2016, Jul-15, Volume: 215 Topics: Adenosine; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Propensity Score; Registries; Republic of Korea; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid	2016
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome. Pharmacogenomics, 2016, Volume: 17, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Humans; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine	2016
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ open, 2016, 05-12, Volume: 6, Issue:5 Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine	2016
Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, Volume: 50, Issue:5 Topics: Adenosine; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Preoperative Care; Retrospective Studies; Ticagrelor; Ticlopidine	2016
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. International journal of cardiology, 2016, Aug-01, Volume: 216 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks. European heart journal, 2016, 09-14, Volume: 37, Issue:35 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. Thrombosis research, 2016, Volume: 144 Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine	2016
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PloS one, 2016, Volume: 11, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine	2016
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. Genetics and molecular research : GMR, 2016, May-25, Volume: 15, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticagrelor; Ticlopidine	2016
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. Platelets, 2016, Volume: 27, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. Journal of the Chinese Medical Association : JCMA, 2016, Volume: 79, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine	2016
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution. International journal of cardiology, 2016, Oct-15, Volume: 221 Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Medication Therapy Management; Postoperative Complications; Risk Adjustment; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Treating Acute Coronary Syndrome. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2015, Volume: 30, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2015
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. European heart journal, 2016, Nov-21, Volume: 37, Issue:44 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome	2016
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy. Journal of endourology, 2016, Volume: 30, Issue:10 Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy	2016
Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2016, Volume: 30, Issue:11 Topics: Adenosine; Animals; Blood Platelets; Bone Regeneration; Clopidogrel; Dipyridamole; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Platelet Activation; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine	2016
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Platelets, 2016, Volume: 27, Issue:6 Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Vitamin D	2016
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial. Scientific reports, 2016, 08-24, Volume: 6 Topics: Adenosine; Adult; China; Clopidogrel; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Male; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Young Adult	2016
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization. International journal of cardiology, 2016, Nov-15, Volume: 223 Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medication Therapy Management; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2016
In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Platelets, 2017, Volume: 28, Issue:3 Topics: Adenosine; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Stents; Thrombosis; Ticagrelor; Ticlopidine	2017
Protective Effects of Ticagrelor on Myocardial Injury After Infarction. Circulation, 2016, Nov-29, Volume: 134, Issue:22 Topics: Adenosine; Animals; Blood Platelets; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Myocardial Infarction; Platelet Aggregation Inhibitors; Random Allocation; Swine; Ticagrelor; Ticlopidine	2016
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (C American heart journal, 2016, Volume: 181 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Canada; Clopidogrel; Drug Substitution; Emergency Medical Services; Emergency Service, Hospital; Female; Hemorrhage; Hospitalization; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Young Adult	2016
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. International journal of cardiology, 2017, Feb-01, Volume: 228 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. International journal of cardiology, 2017, Feb-01, Volume: 228 Topics: Adenosine; Aged; Canada; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after American heart journal, 2017, Volume: 183 Topics: Adenosine; Adenosine Diphosphate; Aged; Cardiovascular Diseases; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Patient Preference; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Antagonists; Ticagrelor; Ticlopidine	2017
Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile. Journal of clinical epidemiology, 2017, Volume: 86 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Epidemiologic Studies; Female; Humans; Latin America; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2017
Switching from ticagrelor to clopidogrel: New answers and further questions. Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2 Topics: Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2017
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine	2017
Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. Cardiovascular research, 2017, Volume: 113, Issue:1 Topics: Adenosine; Animals; Blood Coagulation; Blood Platelets; Carotid Artery Injuries; Cells, Cultured; Clopidogrel; Disease Models, Animal; Down-Regulation; Endothelial Cells; Equilibrative Nucleoside Transporter 1; Fibrinolytic Agents; Humans; Male; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Proteasome Endopeptidase Complex; Proteolysis; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thromboplastin; Thrombosis; Ticagrelor; Ticlopidine; Time Factors; Tumor Necrosis Factor-alpha	2017
Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients. Basic & clinical pharmacology & toxicology, 2017, Volume: 120, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; Clopidogrel; Cyclic AMP; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine	2017
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. European heart journal, 2017, Jun-01, Volume: 38, Issue:21 Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine	2017
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. European heart journal, 2017, Mar-21, Volume: 38, Issue:12 Topics: Adenosine; Antithrombins; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Endocardium; Heart Atria; Humans; Plasminogen Activator Inhibitor 1; Purinergic P2Y Receptor Antagonists; Thromboplastin; Ticagrelor; Ticlopidine; Tumor Necrosis Factor-alpha	2017
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Asian People; Cell Adhesion Molecules; Clopidogrel; Cryopreservation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Vasodilator Agents	2018
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. The American journal of cardiology, 2017, Apr-15, Volume: 119, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Black People; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; White People	2017
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients. Frontiers of medicine, 2017, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. Resuscitation, 2017, Volume: 114 Topics: Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Humans; Hypothermia, Induced; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine	2017
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. International journal of cardiology, 2017, May-15, Volume: 235 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine	2017
Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI. International heart journal, 2017, Apr-06, Volume: 58, Issue:2 Topics: Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine	2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, Mar-29, Volume: 6, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Troponin	2017
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation. Heart, lung & circulation, 2018, Volume: 27, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Slovenia; Survival Rate; Ticagrelor; Ticlopidine; Time Factors	2018
Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC cardiovascular disorders, 2017, 04-05, Volume: 17, Issue:1 Topics: Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Survival Rate; Ticagrelor; Ticlopidine; Time Factors	2017
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2017, Volume: 23, Issue:3 Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine	2017
Use of Platelet Function Testing Before Pipeline Embolization Device Placement: A Multicenter Cohort Study. Stroke, 2017, Volume: 48, Issue:5 Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Intracranial Embolism; Intracranial Thrombosis; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Young Adult	2017
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The Journal of invasive cardiology, 2017, Volume: 29, Issue:10 Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethnicity; Female; Graft Occlusion, Vascular; Hemorrhage; Hospital Mortality; Humans; Male; Michigan; Middle Aged; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Time Factors	2017
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. Journal of cardiovascular translational research, 2017, Volume: 10, Issue:4 Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Signal Transduction; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascular pharmacology, 2017, Volume: 93-95 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein	2017
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. The Annals of pharmacotherapy, 2017, Volume: 51, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Safety; Ticagrelor; Ticlopidine	2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American heart journal, 2017, Volume: 186 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator	2017
A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures. Neurosurgery, 2017, Oct-01, Volume: 81, Issue:4 Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Drug Costs; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult	2017
Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. International journal of cardiology, 2017, Aug-01, Volume: 240 Topics: Adenosine; Animals; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Endothelium, Vascular; Hyperplasia; Male; Neointima; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Random Allocation; Swine; Ticagrelor; Ticlopidine; Tomography, Optical Coherence; Treatment Outcome	2017
Critical Role of P2Y Journal of immunology (Baltimore, Md. : 1950), 2017, 07-01, Volume: 199, Issue:1 Topics: Adenosine; Animals; Autoimmune Diseases; Cell Differentiation; Cells, Cultured; Clopidogrel; Colitis; Diabetes Mellitus, Experimental; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Interleukin-17; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Knockout; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Th17 Cells; Ticagrelor; Ticlopidine; Trinitrobenzenesulfonic Acid	2017
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention. The American journal of cardiology, 2017, Jul-15, Volume: 120, Issue:2 Topics: Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome. Pharmacotherapy, 2017, Volume: 37, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; United States	2017
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Disease Management; Female; Hospitalization; Humans; Hyperglycemia; Italy; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine	2017
The impact of clinical and genetic factors on ticagrelor and clopidogrel antiplatelet therapy. Pharmacogenomics, 2017, Volume: 18, Issue:10 Topics: Adenosine; Aged; Clopidogrel; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors	2017
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. PloS one, 2017, Volume: 12, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine	2017
Reversal of the platelet inhibitory effect of the P2Y Clinical research in cardiology : official journal of the German Cardiac Society, 2017, Volume: 106, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. Kardiologia polska, 2017, Volume: 75, Issue:6 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine	2017
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C192 Gene Mutation After Percutaneous Coronary Interventions (PCI). Medical science monitor : international medical journal of experimental and clinical research, 2017, Aug-07, Volume: 23* Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Mutation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2017
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine	2018
The impact of CYP2C192, CYP4F23, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:8 Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P450 Family 4; Female; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2017
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. Pharmacotherapy, 2017, Volume: 37, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization Review; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine	2017
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy. Coronary artery disease, 2018, Volume: 29, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine	2018
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome. Journal of managed care & specialty pharmacy, 2017, Volume: 23, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Retrospective Studies; Secondary Prevention; Ticagrelor; Ticlopidine	2017
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor? Internal medicine journal, 2017, Volume: 47, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Withholding Treatment	2017
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. The American journal of case reports, 2017, Sep-01, Volume: 18 Topics: Adenosine; Brain Infarction; Clopidogrel; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Polycythemia Vera; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thrombocytosis; Ticagrelor; Ticlopidine	2017
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry. Journal of thrombosis and thrombolysis, 2017, Volume: 44, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Registries; Retrospective Studies; Ticagrelor; Ticlopidine	2017
Contemporary use of P2Y Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1 Topics: Adenosine; Adult; Aged; Clopidogrel; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Poland; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine	2018
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience. Therapeutic advances in cardiovascular disease, 2017, Volume: 11, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Nov-20, Volume: 13, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2017
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. European journal of clinical investigation, 2018, Volume: 48, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine	2018
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. European journal of clinical pharmacology, 2018, Volume: 74, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome	2018
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Community Pharmacy Services; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Delivery of Health Care, Integrated; Drug Costs; Female; Genetic Testing; Humans; Male; Markov Chains; Medication Therapy Management; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Point-of-Care Testing; Precision Medicine; Predictive Value of Tests; Program Evaluation; Quality of Life; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; United States	2018
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. Journal of atherosclerosis and thrombosis, 2018, Aug-01, Volume: 25, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2018
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine	2018
Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries. Clinical drug investigation, 2018, Volume: 38, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Aged; Asia; China; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Female; Health Care Costs; Hong Kong; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Republic of Korea; Taiwan; Ticagrelor; Ticlopidine	2018
Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervent Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:1 Topics: Adenosine; Adult; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Endothelium, Vascular; Female; Humans; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prognosis; Proteoglycans; Ticagrelor; Ticlopidine; Treatment Outcome	2018
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Costs and Cost Analysis; Female; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Patient Acceptance of Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine	2018
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Chinese medical journal, 2018, Sep-05, Volume: 131, Issue:17 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome	2018
[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice]. Kardiologiia, 2019, Jun-20, Volume: 59, Issue:5S Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome	2019
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests	2021
A rare case of late-onset ticagrelor-induced sinus arrest. Asian cardiovascular & thoracic annals, 2021, Volume: 29, Issue:9 Topics: Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sinus Arrest, Cardiac; Ticagrelor	2021
The effect of ticagrelor on microarterial thrombosis in an experimental model. Journal of plastic surgery and hand surgery, 2021, Volume: 55, Issue:5 Topics: Adenosine; Animals; Clopidogrel; Models, Theoretical; Platelet Aggregation Inhibitors; Rats; Thrombosis; Ticagrelor; Ticlopidine	2021
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI. JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71, Issue:2(A) Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2021
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. Advances in therapy, 2021, Volume: 38, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Asian People; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine	2021
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor	2021
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel. Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:4 Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine	2023
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor. Minerva cardiology and angiology, 2023, Volume: 71, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine	2023
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy. Frontiers in immunology, 2022, Volume: 13 Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Ticlopidine	2022
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study. International journal of clinical pharmacy, 2023, Volume: 45, Issue:2 Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome	2023
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic. Medicina (Kaunas, Lithuania), 2022, Dec-30, Volume: 59, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome	2022